Use of gaboxadol for the treatment of non-24 hour sleep-wake disorder
AssigneeOvid Therapeutics Inc.
InventorMatthew During
Life of this patent
Estimating the term…
Abstract
Treatment of non 24 sleep wake disorder using gaboxadol or a pharmaceutically acceptable salt thereof is provided. Pharmaceutical compositions that may be used to improve one or more symptoms of non 24 sleep wake disorder are provided.
Claims11
A method of treating non 24 hour sleep wake disorder comprising administering to a patient in need thereof about 0.05 mg to about 30 mg gaboxadol or a pharmaceutically acceptable salt thereof, wherein the method provides improvement in at least one symptom of the 24 hour sleep wake disorder selected from the group consisting of irregular sleep patterns, irregular circadian rhythms, apraxia, cognitive dysfunction, difficulties concentrating, confusion, depressed mood, diarrhea, nausea, hair loss, headache, impaired balance, photosensitivity, joint pain, ataxia, menstrual irregularities, muscle pain, suicidal thoughts, weight gain, and hallucinations.
A method of treating non 24 hour sleep wake disorder comprising administering to a patient in need thereof gaboxadol or a pharmaceutically acceptable salt thereof wherein the method provides an in vivo plasma profile of gaboxadol comprising a Cmax less than about 400 ng/ml.
A method of treating non 24 hour sleep wake disorder comprising administering to a patient in need thereof gaboxadol or a pharmaceutically acceptable salt thereof wherein the method provides an in vivo plasma profile of gaboxadol comprising a AUC6-12 of less than about 900 ng·hr/ml.
Dependencies are inferred from the claim text.